Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
The Body Covers:
The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Chicago, Illinois

September 14-17, 2003

• Browse the complete index of our coverage.

• Download the PDF version of our complete conference coverage (600K).

Highlights

After the release of the guidelines is there a different understanding of when's the best time to start treatment? Judy Aberg, M.D., reports from ICAAC.

In a large comparison study of 1,119 antiretroviral-naive patients who started HIV therapy, treatment regimens containing efavirenz, nevirapine or Kaletra were found to be the most potent options. Gerald Pierone, Jr., M.D., reports."

"Both resistance testing and therapeutic drug monitoring are crucial tools to manage both treatment-naive and treatment-experienced patients. Mark Holodniy, M.D., explains why."

A Spanish study confirms ACTG 5095 and finds that the three-nucleoside regimen in Trizivir was not quite as potent as the efavirenz- or nevirapine-containing regimens for initial therapy. Andrew Pavia, M.D., reports.

 


Coverage Provided By:
Judith A. Aberg, M.D. Cal Cohen, M.D., M.S. Edwin DeJesus, M.D.
Robert Frascino, M.D. Keith Henry, M.D. Mark Holodniy, M.D., F.A.C.P., C.I.C.
Andrew T. Pavia, M.D. Gerald Pierone, Jr., M.D. Paul E. Sax, M.D.
Corklin Steinhart, M.D., Ph.D. Timothy Wilkin, M.D., M.P.H. Benjamin Young, M.D., Ph.D.


About ICAAC 2003

The Body's ICAAC 2003 coverage spans a wide array of individual presentations and symposia, as well as research summaries of some of the hottest topics in HIV research.

For more information on ICAAC, please visit the conference's Web site. You may also view the conference's preliminary program online or download it in PDF form (3.3MB).

Funding for coverage of this conference is provided, in part, by unrestricted educational grants from Boehringer Ingelheim, Gilead Sciences, Inc., GlaxoSmithKline and Ortho Biotech Products, L.P.

All coverage is © 2003 Body Health Resources Corporation.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement